Julia Camps-Herrero
Dr Julia Camps-Herrero is a breast radiologist and also the Corporate Chief of Breast Health in four Ribera Salud hospitals (University Hospitals of Torrejon, POVISA, Vinalopó and Polusa). Since 1999 she is an active researcher in multimodality breast radiology, with a special interest in contrast imaging (MRI and CEM) and minimally invasive procedures. Dr Camps-Herrero is an active speaker in Latin America and Europe, where she has been invited to lecture in more than 400 presentations. She was appointed Breast Section Editor for EURORAD during 2007-2019 and has held various scientific positions, among others: Chairman of the ECR 2012 Breast Subcommittee, Chairman of the Spanish Senology Congress in 2015, and member of the Programme Planning Committee for ECR 2015, 2016 and 2022. Currently, she is a board member of SEDIM (Spanish Breast Imaging Society) and held the position of President of the European Society of Breast Imaging (EUSOBI) during 2018-2020. In November 2026 the Spanish Society of Radiology will endow her the Lifetime Achievement Award in Radiology 2026.
-------------------------------------------------------------------------------------------------
Title: Surveillance and CEM
Women with a personal history of breast cancer (PHBC) are at increased risk of either a local recurrence or a new primary breast cancer. International guidelines recommend annual mammography as the only surveillance technique (ASCO, NCCN, ESMO) but a mammogram is less sensitive in the post-surgical due to post-treatment changes (fat necrosis, surgical scars). Furthermore, the sensitivity of mammography for the detection of breast cancer is lower in patients with a PHBC than with patients without a history of breast cancer (sensitivity of 65.4% in the former and sensitivity of 76.5% in the latter group) and it is lower during the first five years after treatment than later (sensitivity of 60.2% during the first five years and of 70.8% after five years). These facts (very low sensitivity for recurrence and even less during the first five years when the most aggressive cancers recur) make mammography a substandard technique in these patients Morphologic imaging techniques (mammography, US, DBT) appear to be incapable of preventing underdiagnosis of relevant cancers in PHBC. Functional imaging modalities (MRI, contrast-enhanced mammography) are not limited by scar tissue or breast tissue density and thus show increased cancer detection and decreased interval cancer rates compared to morphological techniques.
Title: Translating Imaging Findings into the Operating
Theatre
Managed and payment processed by:
KC Jones conference&events Ltd
Telephone: 01332 227773
Email: bsbr@kc-jones.co.uk